Company intelligence / Profile preview
Fauna Bio
Emeryville, California, United Statesfaunabio.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Preclinical
01
Overview
Fauna Bio is developing drug candidates by studying disease resistance mechanisms in animals, particularly hibernating mammals. The company has partnerships with Eli Lilly and Novo Nordisk for obesity drug targets and is planning to expand into heart failure research.
- Therapeutic areas
- Metabolic DisordersEndocrinologyRheumatologyCardiovascularNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Eli LillyNovo Nordisk
Beyond the preview
Go deeper on Fauna Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fauna Bio.